Retatrutide is a promising “triple agonist” weight loss medication that has shown impressive results in clinical trials. However, it is not currently FDA-approved for any condition and is expected to remain in the investigational phase for the near future. So far, as of late 2025, its manufacturer, Eli Lilly, has seven additional Phase III clinical trials expected to conclude in 2026. While widespread patient access is not anticipated until a potential FDA approval in 2026 or later, there are structured pathways to access investigational drugs before they reach the market.
Can You Access Retatrutide Before Full Approval?
Currently, direct access to Retatrutide before FDA approval is extremely limited and typically not available to the general public. It is not legally available for individual prescription at standard or compounding pharmacies.
The table below summarizes the only legitimate ways to access Retatrutide before it is commercially available.
| Pathway | Description | Current Status for Retatrutide (Late 2025) |
|---|---|---|
| Clinical Trials | Participation in official research studies conducted by Eli Lilly. | Available. This is the primary legal access point. Multiple active Phase III trials are ongoing. |
| Compassionate Use / Expanded Access | A program for patients with serious conditions and no other treatment options. | Not currently available. As of May 2025, no public expanded access program was active for Retatrutide. |
| Legal Compounding | Custom medication prepared by a licensed pharmacy for an individual patient. | Explicitly prohibited. The FDA states Retatrutide is not a component of any FDA-approved drug and “cannot be used in compounding under federal law”. |
| Commercial or “Gray Market” | Products sold online by unregulated suppliers, often labeled “for research” or “not for human consumption.” | Illegal and dangerous. The FDA has issued warning letters to companies illegally selling unapproved Retatrutide. |
Enrolling in Clinical Trials
Clinical trials are the only recommended and legal way to try Retatrutide today. Eli Lilly is conducting a comprehensive Phase III program, with trials studying the drug for obesity and related conditions like knee osteoarthritis.
-
Where to Find Them: The U.S. National Library of Medicine maintains ClinicalTrials.gov, a searchable database of all ongoing studies. You can search for “retatrutide” to find actively recruiting trials.
-
Eligibility and Application: Each trial has strict inclusion and exclusion criteria (e.g., specific BMI, medical history, age). You cannot apply directly; you must express interest through the study sites listed, which will evaluate your eligibility.
Compassionate Use Programs
Compassionate use (or expanded access) is a regulatory pathway that allows the use of an investigational drug outside of a clinical trial for patients with a serious or immediately life-threatening condition who have no comparable treatment options. The goal is primarily therapeutic, not experimental. For Retatrutide, this pathway is not currently active, meaning the manufacturer is not accepting requests, likely because the drug is still being tested in broader clinical populations.
Are There Legal or Ethical Concerns with Early Access?
Pursuing illegal early access carries significant risks. The FDA has issued strong warnings about unapproved weight loss drugs.
-
Safety and Quality Risks: Products sold outside regulated channels are of unknown quality and purity. They may contain incorrect doses, different ingredients (like unstudied salt forms), contaminants, or no active drug at all.
-
Legal Risks: Selling and distributing unapproved versions of Retatrutide is illegal. The FDA has taken enforcement action, including warning letters and seizures, against companies engaged in this activity.
-
Ethical and Market Impact: Widespread “gray market” use can complicate clinical trial recruitment and may create inaccurate perceptions of the drug’s real-world safety and efficacy before it is fully studied.
Should You Wait or Try to Access It Now?
Should You Wait or Try to Access Retatrutide Now?
So, should you consider trying to get it now, or is waiting the better move? Really, it comes down to your personal health picture and how much uncertainty you’re comfortable with.
You might be a good fit for a clinical trial if:
-
You meet typical enrollment criteria (like having obesity or overweight with a related health condition), and
-
You’re open to the unknowns of an investigational treatment—including potential side effects and the chance of receiving a placebo.
On the other hand, waiting for FDA approval is likely your best and safest choice if:
-
You don’t qualify for or can’t find a suitable trial.
-
This way, you can be confident you’re receiving a product that’s been fully vetted for safety, strength, and quality.
While you wait, a practical step is to talk to your doctor about currently approved medications, such as tirzepatide (Zepbound) or semaglutide (Wegovy).
Other Weight Loss Options
Active Ingredient: Semaglutide
Semaglutide is a GLP-1 receptor agonist only. It mimics the hormone GLP-1, which helps regulate blood sugar and appetite.
| Brand Name | Manufacturer | Route | FDA-Approved Use | FDA Approval Year |
|---|---|---|---|---|
| Ozempic | Novo Nordisk | Injectable (weekly) | Type 2 diabetes; Cardiovascular risk reduction | 2017 |
| Wegovy | Novo Nordisk | Injectable (weekly) | Chronic weight management | 2021 |
| Rybelsus | Novo Nordisk | Oral (daily tablet) | Type 2 diabetes | 2019 |
Active Ingredient: Tirzepatide
Tirzepatide is a dual agonist — it activates GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP activity may enhance weight loss and blood sugar control compared to GLP-1–only drugs.
| Brand Name | Manufacturer | Route | FDA-Approved Use | FDA Approval Year |
|---|---|---|---|---|
| Mounjaro | Eli Lilly | Injectable (weekly) | Type 2 diabetes | 2022 |
| Zepbound | Eli Lilly | Injectable (weekly) | Chronic weight management, Obstructive Sleep Apnea | 2023 |
Active Ingredient: Retatrutide
Retatrutide is an experimental triple receptor agonist—activating GLP-1, GIP, and glucagon receptors—designed to enhance weight loss and metabolic control.
| Brand Name | Manufacturer | Route | Potential FDA-Approved Use | FDA Approval Year |
|---|---|---|---|---|
| — | Eli Lilly and Company | Injectable (weekly) | Investigational use for obesity, type 2 diabetes, nonalcoholic fatty liver disease, Obstructive Sleep Apnea, Osteoarthritis Pain Relief | Not yet approved (In clinical trials Phase III) |
Key Takeaways
-
Retatrutide is not yet FDA-approved and cannot be legally prescribed or obtained from a pharmacy.
-
Clinical trial participation is the only recommended access pathway currently available. You can search for active trials on ClinicalTrials.gov.
-
Avoid illegal online sellers. Products from these sources are dangerous and violate federal law.
-
Consult your healthcare provider to discuss whether joining a clinical trial is appropriate for you or if an existing approved therapy is a better current option.
Heally can connect you to a knowledgeable doctor who can help you find the best way forward. You don’t have to navigate this alone; let’s find the right solution together! Schedule your free consult!
Sources
- New England Journal of Medicine: Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- JAMA Network: FDA Issues Warnings About Compounded Versions of Semaglutide and Tirzepatide
- U.S. Food and Drug Administration (FDA): Expanded Access: Information for Patients
- U.S. Food and Drug Administration (FDA): FDA In Brief: FDA Warns Consumers Not to Use Counterfeit or Unapproved Versions of Popular Weight Loss and Diabetes Drugs
- U.S. National Library of Medicine: Find a Clinical Trial: ClinicalTrials.gov
- Nature Reviews Endocrinology: Next Generation of Incretin-Based Therapy for Obesity and Type 2 Diabetes
- The Lancet: Efficacy and Safety of the GLP-1 and Glucagon Receptor Dual Agonist Survodutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
- FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide
- FDA Label: WEGOVY (Semaglutide Injection) Medication Guide
- FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide
- FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide
- FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide
Important Medical Information and Disclaimers
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, and before starting any medication.
Prescription GLP-1 medications like semaglutide (Ozempic®, Wegovy®, Rybelsus®) and tirzepatide (Mounjaro®, Zepbound®) are FDA-approved for specific uses and must be used under the supervision of a licensed healthcare provider. They are not over-the-counter supplements.
Compounded Drug Warning
The FDA has not approved compounded drugs and has issued safety alerts about dosing errors, product contamination, and other quality concerns. Compounded drugs are custom formulations made by pharmacies and may vary in quality, safety, and effectiveness, which can increase the risk of side effects or treatment failure. The FDA has warned against using these versions due to issues with incorrect ingredients, poor storage, or improper dosage. Always get medications from a licensed pharmacy with a valid prescription.
Individual Results May Vary
Responses to GLP-1 therapy can vary from person to person. Factors such as diet, physical activity, sleep quality, underlying medical conditions, other medications, and individual metabolism can all influence both side effects and overall results. Clinical trial outcomes may differ from real-world experiences.
Possible Side Effects of GLP-1 medications may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach pain or discomfort
- Decreased appetite
- Indigestion or gas
- Redness, itching, or soreness at the injection site
Most side effects are mild to moderate and may improve as your body adjusts to treatment. If you experience severe or persistent symptoms, contact your healthcare provider promptly.
Boxed Warning (Thyroid C-Cell Tumor Risk)
GLP-1 receptor agonists, including semaglutide, carry an FDA boxed warning regarding the potential risk of thyroid C-cell tumors. Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
When to Seek Immediate Medical Attention
Contact your healthcare provider or seek emergency care if you experience:
- Severe abdominal pain that does not go away
- Signs of an allergic reaction (rash, swelling, difficulty breathing)
- Symptoms of pancreatitis (severe abdominal pain, vomiting)
- Symptoms of severe dehydration (dizziness, confusion, rapid heartbeat)
FDA Adverse Event Reporting
